RITC2026

• Validated, scalable multimodal–data solutions that improve personalised management of multimorbid patients
• Demonstrated reduction in time to diagnosis, improved monitoring of disease progression and relapses, and enhanced detection of co-morbidities
• Effective remote monitoring and reporting workflows that enable a shift from in-patient to out-patient care and reduce healthcare utilisation
• Decision-support tools for optimised treatment strategies, including drug selection, dosing and management of polypharmacy, leading to fewer adverse interactions
• Increased patient adherence to long-term regimens through data-driven monitoring and support
• Holistic system models demonstrating integration of technical, organisational, regulatory and behavioural components
• Robust data pipelines and governance frameworks for secure, interoperable use of multi-modal health data
• Business and value models outlining paths to commercialisation and health system adoption

• Target population: multimorbid patients (≥2 chronic diseases requiring management)
• Focus on use of multimodal data (clinical, wearable, imaging, omics, patient-reported, etc.) to support personalised interventions
• Address at least one of the following: detection/characterisation of co-morbidities; disease diagnosis, follow-up or monitoring; remote monitoring for out-patient care; decision support for treatment strategies; multi-treatment management; adherence support
• Solutions must be at Technology Readiness Level (TRL) sufficient for testing in controlled real-world settings (i.e., mature prototypes or pilot deployments)
• Must adopt and integrate all six enabling system elements
• Proposals must detail a clear plan for data acquisition, integration, processing, analytics, interoperability, privacy/security and ethical compliance
• Transnational consortium must include at least one clinical partner and at least one SME or industry partner
• Clinical studies are eligible; large-scale clinical trials are out of scope